In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

ViroGates nets DKK60mm through IPO on Nasdaq First North

Executive Summary

In its oversubscribed initial public offering on Nasdaq First North Denmark, ViroGates AS (prognostic biomarker tools used in clinical decision making) sold 824k new shares at DKK91 apiece, for net proceeds of DKK60mm ($9.38mm).
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Laboratory Testing Services
  • Medical Devices
    • Diagnostic Equipment & Supplies
  • Services
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

Advertisement
UsernamePublicRestriction

Register